Aaron Royston - 27 Jul 2026 Form 4 Insider Report for ACHIEVE LIFE SCIENCES, INC. (ACHV)

Reporting relationship: Director
Issuer ticker: ACHV
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2026, 17:22:59 UTC
Prior SEC filing: 27 Apr 2026
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: Sandra Thomson as attorney-in-fact

Key filing fact

Aaron Royston filed Form 4 for ACHIEVE LIFE SCIENCES, INC. (ACHV) on 29 Jul 2026.

Key facts

This page summarizes Aaron Royston's Form 4 filing for ACHIEVE LIFE SCIENCES, INC. (ACHV).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 29 Jul 2026, 17:22.

Change

Previous filing in this sequence was filed on 27 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001727703 Primary reporting owner

Royston Aaron

Relationship: Director
Address: 22722 29TH DR. SE, SUITE 100, BOTHELL
Signature: Sandra Thomson as attorney-in-fact
Signature date: 29 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACHV transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +25,000
Change %
Price: $0.000000^*
Shares after: 25,000
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $6.18
Footnotes: F1

ACHV transaction Derivative

Restricted Stock Unit (RSU)

Award

Transaction value
Shares: +16,700
Change %
Price: $0.000000^*
Shares after: 16,700
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,700
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.

Footnote F3

Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC remarks

Dr. Royston is a member of venBio Global Strategic GP V, LLC, which is the general partner of venBio Global Strategic Fund V, L.P. ("venBio V"), and is a member of the board of directors of the Issuer. These options and RSUs are held by Dr. Royston for the benefit of venBio V. Pursuant to policies of venBio Partners, the manager of venBio V, with respect to director compensation, upon the exercise of these options, the vesting and settlement of these RSUs, and the sale of the underlying securities, the proceeds will be remitted to venBio V. Dr. Royston disclaims beneficial ownership over the shares underlying the options and RSUs held for the benefit of venBio V except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be deemed an admission of beneficial ownership for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, or any other purpose.